KRAS and non-small cell lung carcinoma: In this study, we verified the technical efficiency of a novel dPCR platform (QIAcuityTM Digital PCR System, QIAGEN; Hilden, Germany) by applying it to a retrospective series of archived NSCLC liquid biopsy specimens (n = 25 EGFR/KRAS wild type, n = 25 EGFR/KRAS mutated cases) previously tested with NGS.